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Background: 90-day mortality (90 DM) has been proposed as a clinical indicator in radiotherapy deliv-
ered in a curative setting. No large scale assessment has been made. Its value in allowing robust compar-
isons between centres and facilitating service improvement is unknown.
Methods: All radiotherapy treatments delivered in a curative setting over seven years were extracted
from the local electronic health record and linked to cancer registry data. 90 DM rates were assessed
and factors associated with this outcome were investigated using logistic regression. Cause of death
was identified retrospectively further characterising the cause of 90 DM.
Results: Overall 90 DM was 1.25%. Levels varied widely with diagnosis (0.20–5.45%). Age (OR 1.066,
1.043–1.073), year of treatment (OR 0.900, 0.841–0.969) and diagnosis were significantly associated with
90 DM onmulti-variable logistic regression. Cause of death varied with diagnosis; 50.0% post-operative in
rectal cancer, 40.4% treatment-related in head and neck cancer, 59.4% disease progression in lung cancer.
Conclusion: Despite the drive to report centre level comparative outcomes, this study demonstrates that
90 DM cannot be adopted routinely as a clinical indicator due to significant population heterogeneity and
low event rates. Further national investigation is needed to develop a meaningful robust indicator to deli-
ver appropriate comparisons and drive improvements in care.
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2017) xxx–xxx
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).90 day mortality has been suggested in the English NHS as a
clinical indicator following radiotherapy delivered in a curative
setting (RDCS) [1]. It is proposed that this will deliver comparative
assessments of quality of care across providers. Such assessments,
aiming to inform patient choice and support service improvement
[2], are now routinely used in surgery [3–6] and are increasingly
seen across a range of other healthcare interventions, including
chemotherapy [7–9]. It has been shown, however, that in settings
where rates of early mortality are low, and where procedures are
infrequent, indicators may not be adequately powered to identify
outlying practice [10,11]. This may result in failure to identify
poorly performing centres, complacency amongst those wrongly
identified as performing in line with expectations and significantreputational damage and patient anxiety in centres falsely
identified as underperforming. In addition, the ambition to trans-
form services into learning organisations [12] depends upon the
availability of indicators to quantify and understand variations in
care and outcomes.
In this context it is vital to ensure the indicators used are appro-
priate. A number of requirements must be met to ensure this: data
must be robust; the population relatively homogeneous; the indi-
cator must reflect quality and be adequately powered to identify
outlying practice. Failure to meet these objectives may render
them at best unhelpful and at worst counter-productive.
Approximately 65,000 radiotherapy treatments are delivered in
England each year in a curative setting [13]. Treatment courses
range from short pre-operative, definitive longer course radiother-
apy or chemo-radiotherapy, through to post-operative adjuvant
radiotherapy. The toxicities of these complex pathways and the
populations treated within them vary widely. Where significant
toxicity is experienced quality supportive care is key to ensuringurative
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2 Caution is required in the implementation of 90-day mortality indicators for radiotherapy in a curative settinggood outcomes and the avoidance of harm. Unfortunately, for some
patients it is disease progression, during or very shortly after
treatment that results in death. Identifying the primary cause of
mortality is, however, complex and it is unclear if a single indicator
has value across all treatment approaches.
To date only small scale assessments of 90 DM following RDCS
have been carried out with overall rates of around 2.3% reported
[14]. With this evidence it is unclear if the 90 DM indicator can
meet the required standards to ensure valid, clinically meaningful
outcomes in this setting.
This study aimed to investigate 90 DM in a large 7-year regional
cohort in England. It assessed the factors associated with 90 DM,
considered the value of this indicator in guiding service improve-
ments and investigated its potential to provide robust comparisons
between centres.Materials and methods
All radiotherapy episodes delivered in Leeds Cancer Centre
(LCC), between January 2004 and December 2010, were identified
using the electronic patient record. Patient demographics (date of
birth and sex) and treatment information (date of treatment,
planned fractionation, dose, treatment intent and site treated)
were extracted from this resource. These data were linked to the
cancer registrations held by the National Cancer Registration and
Analysis Service (Northern and Yorkshire), ensuring robust diag-
nostic, socioeconomic status (SES) and date of death information
were available for all linked records. SES was derived on the basis
of rank quintile of the Index of Multiple Deprivation (IMD), (ONS
2010 version) [15], for the Lower Super Output Area (population
defined geographical region of approximately 1500 people [16])
of residence at diagnosis.
Diagnosis was defined using International Classification of Dis-
eases (ICD-10) codes [17]. Clinically recognised diagnostic groups
were formed by combining diagnoses; Brain tumours included all
central nervous system tumours, Head and Neck (H + N) cancer
encompassed all cancers arising between the hypopharynx (inferi-
orly) and nasopharynx (superiorly) and salivary gland tumours,
excluding sarcomas. See supplementary Table 1s for ICD10 group-
ings. A significant number of patients had multiple malignant diag-
noses and were identified as such. Small diagnostic groups were
combined to form the ‘‘Other” category, this included, but was
not limited to, thyroid cancer, and male and female genital tract
tumours not otherwise classified.
Intent of treatment was defined using a combination of treat-
ment dose, fractionation, intent specified by clinicians and depart-
mental protocols. RDCS included all neo-adjuvant, adjuvant and
primary radiotherapy/chemo-radiotherapy. Throughout the study
period, treatment was delivered within well-defined clinical proto-
cols with limited change over time. To ensure that patients only
entered the cohort once and that fragmented courses (e.g. where
2 phases were recorded separately) were not considered twice,
only the first episode was considered. Exclusions were made to
limit this investigation to adult RDCS treatments, for solid organ
tumours and to ensure data quality (Fig. 1). Patients under the
age of 25 are treated within the paediatric and young adolescent
practice and were therefore excluded.
LCC is a university affiliated centre serving a population of
2.8 million (the second largest UK radiotherapy centre). Consul-
tant clinical oncologist numbers increased from 18 to 30 during
the study period. All are site specialised to a maximum of three
primary diagnostic groups. LCC is resourced through a national
NHS tariff system (reflecting treatment planning complexity
and separately the number of fractions and complexity of
delivery).Please cite this article in press as: Spencer K et al. Caution is required in the im
setting: A retrospective population-based analysis of over 16,000 episodes. Ra90-day mortality
The proportion of people dying within 90-days of the start of
treatment was assessed. The start of treatment was used as the ref-
erence date providing a consistent time point across all fractiona-
tion patterns delivered, ensuring capture of deaths occurring on
treatment and aligning with the methodology used in other inter-
ventions [18]. The dependent variable, death within 90-days, was
considered as a binary outcome. Factors potentially impacting
upon 90 DMwere considered using logistic regression. Explanatory
variables included, age at the start of radiotherapy (a continuous
variable), sex, socioeconomic status, primary diagnosis and year
of treatment. Colorectal cancer was used as the baseline diagnostic
group within the logistic regression model, representing the largest
disease group including both male and female patients across a
wide range of age and SES. Patients in whom the SES was not
known (506 individuals) were omitted from regression analysis.Cause of death (COD)
For all patients dying within 90 days of the start of radiotherapy
COD was determined (malignancy, treatment, co-morbidity or
post-operative) using death certificate data in combination with
retrospective clinical record review. This assessment was made
in order to determine what is measured by 90 DM and, hence,
the quality of the indicator. Determining the underlying COD can
be challenging. COD was assessed by two investigating clinicians
independently to provide as accurate an assessment as possible.
Further investigation of the H + N and lung cancer populations
was carried out. These two groups were considered due to their
size and the moderate 90 DM rates seen, allowing more in depth
analysis incorporating the impact of anatomical subsite (oropha-
ryngeal versus other H + N sites), morphology (non-small cell ver-
sus small cell lung cancer) and year of treatment. The introduction
of the cancer waiting times directive within the NHS in the early
part of this cohort [19] and increased capacity within the service
in 2008 resulted in a marked reduction in waiting times. Consistent
information on waiting time was only available for the first four
years. Time from decision to treat to first treatment (TTFT) was
determined for this cohort and variation between years assessed
using ANOVA.
Statistical analyses were carried out using STATA IC 14. The
study was approved by the local audit department.Results
The final study population consisted of 16,675 radiotherapy
treatments. Women were the majority of the cohort (10,541
(63.2%)), reflecting the large number of patients (6597 (39.6%))
treated for breast cancer. Prostate cancer (1993 (12%)), colorectal
cancer (1197 (7.2%)), H + N cancer (1165 (7.0%)) and lung cancer
(871 (5.2%)) were the next most frequently treated diagnoses.
The distribution of age and SES were in line with expectations.
The number of treatments delivered each year rose from 2001 to
2699 between 2004 and 2010 (see Table 1).
Overall, 90 DM was 1.25%, but varied widely with diagnosis
ranging from 0.2% in prostate cancer to 5.45% in oesophageal can-
cer. Lung (3.89%) and H + N cancers (3.86%) had moderate levels of
90 DM (see Table 1).
Factors significantly associated with increased 90 DM on uni-
variable logistic regression included increasing age, earlier year
of treatment and individual diagnostic groups (see Table 2). Age
and year retained their significance on multivariable analysis.
Breast (OR 0.248, p < 0.001) and prostate (OR 0.076, p < 0.001) can-
cer treatments were associated with significantly lower 90 DM
than colorectal cancer whilst head and neck cancer (OR 1.837,plementation of 90-day mortality indicators for radiotherapy in a curative
diother Oncol (2017), http://dx.doi.org/10.1016/j.radonc.2017.07.031
Fig. 1. Consort diagram illustrating exclusions to reach final study population.
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90 DM.
Amongst patients who died within 90 days of the start of radio-
therapy for rectal cancer 50.0% of deaths were attributed to post-
operative complications, 28.1% related to comorbid disease and
21.9% disease progression. In contrast, in breast cancer, 78.3% were
due to disease progression and 21.7% co-morbidity. 59.4% of lung
cancer and 46.2% of oesophageal cancer deaths were due to disease
progression with 34.4% and 46.2% due to co-morbidity respec-
tively. H + N cancer was the only diagnosis in which significant
numbers of deaths could be attributed to the treatment delivered
(40.4%) with a further 42.6% due to the primary diagnosis and
17.0% co-morbidity (Fig. 2).
Univariable logistic regression in the H + N cancer population
demonstrated that older age, non-oropharyngeal primary and ear-
lier year of treatment were significantly associated with higher
rates of 90 DM (p < 0.01). Age (OR 1.037 (CI 1.009–1.065)) and year
of treatment (OR 0.788 (CI 0.668–0.929) maintained this signifi-
cance in multivariable analysis (see Table 3). Within the H + N can-
cer population the average TTFT reduced from 67.8 days in 2004 to
40.1 days in 2007, this was significant on one-way ANOVA
(p < 0.001). Further improvement in waiting times is known to
have occurred in the latter part of the cohort. It is not possible to
quantify this.
In lung cancer age and sex were the only factors having a signif-
icant association with 90 DM on univariable analysis. Both main-
tained their significance on multivariable analysis (age, OR 1.068,Please cite this article in press as: Spencer K et al. Caution is required in the im
setting: A retrospective population-based analysis of over 16,000 episodes. Rap = 0.003 (1.022–1.117), male, OR 3.327, p = 0.006 (95%CI 1.412–
7.841) with Small-cell morphology also being associated with sig-
nificantly worse 90 DM (OR 3.592, p = 0.004 (95%CI 1.500–8.603)
(see table 4).Discussion
This study aimed to assess the suitability of 90 day-mortality
as a clinical indicator following radiotherapy delivered in a cura-
tive setting. We report an overall 90 DM of 1.25%. Whilst consistent
with other published series [14] this overall figure concealed wide
variation between cancer sites, age groups and year of treatment.
Further detailed analysis was required to provide information
about how this might reflect the quality of treatment delivered.
In our population 90 DM of 2.59% was seen in those receiving
radiotherapy for colorectal cancer. The significant contribution of
post-operative mortality in this setting (50% of 90 DM) will limit
the value of this indicator in informing non-surgical practice; the
impact of the whole multi-disciplinary team must be recognised
and indicators used that reflect these complex care pathways.
The observed 90 DM seen following breast (0.33%) and prostate
(0.20%) cancer treatments are extremely low. The greatest concern
for breast cancer radiation related mortality is late cardiac toxicity,
many years after treatment [20]. Improved patient selection and
radiotherapy techniques may reduce this, however, these are not
reflected in the 90 DM indicator.plementation of 90-day mortality indicators for radiotherapy in a curative
diother Oncol (2017), http://dx.doi.org/10.1016/j.radonc.2017.07.031
Table 1
Characteristics and 90 day mortality of the treated population.
Total treated % Deaths within 90 days 90 DM
Sex
Female 10,541 63.28 84 0.80
Male 6117 36.72 124 2.03
Age
50 2934 17.61 13 0.44
51–60 3995 23.98 33 0.83
61–70 5353 32.13 50 0.93
71–80 3451 20.72 62 1.80
>80 925 5.55 50 5.41
IMD
Most deprived 3257 19.55 55 1.69
4 2892 17.36 47 1.63
3 2812 16.88 31 1.10
2 3808 22.86 40 1.05
Most affluent 3383 20.31 30 0.89
Unknown 506 3.04 5 0.99
Diagnosis
Colorectal 1197 7.19 31 2.59
Anal 166 1.00 3 1.81
Bladder 353 2.12 15 4.25
Brain 303 1.82 6 1.98
Breast 6596 39.6 22 0.33
Cervical 300 1.8 3 1.00
Lung 871 5.23 31 3.56
H + N 1165 6.99 43 3.69
Multiple 2325 13.96 28 1.20
Oesophageal 202 1.21 11 5.45
Prostate 1993 11.96 4 0.20
Sarcoma 145 0.87 1 0.69
Uterine 327 1.96 2 0.61
Other 715 4.29 8 1.12
Year
2004 1996 11.98 27 1.35
2005 2242 13.46 45 2.01
2006 2555 15.34 33 1.29
2007 2320 13.93 34 1.47
2008 2422 14.54 19 0.78
2009 2425 14.56 21 0.87
2010 2698 16.2 29 1.07
Total 16,658 208 1.25
Table 2
Univariable and multivariable logistic regression of 90 day mortality and case-mix factors.
Co-variable Univariable logistic regression Multivariable logistic regression
OR p 95% CI OR p 95% CI
Age 1.066 <0.001 1.053–1.081 1.058 <0.001 1.043–1.073
Sex
Female 1.000 – 1.000 – –
Male 2.576 <0.001 1.949–3.404 1.393 0.052 0.997–1.947
IMD
Most deprived 1.000 – 1.000 – –
4 0.962 0.846 0.649–1.424 1.042 0.840 0.699–1.554
3 0.649 0.056 0.417–1.011 0.775 0.267 0.494–1.216
2 0.618 0.021 0.410–0.931 0.805 0.310 0.529–1.224
Most affluent 0.521 0.004 0.333–0.815 0.688 0.108 0.435–1.086
Unknown – – – – – –
Year 0.900 0.003 0.839–0.964 0.902 0.004 0.841–0.969
Diagnosis
Colorectal 1.000 – – 1.000 – –
Anal 0.692 0.547 0.209–2.290 1.005 0.994 0.300–3.368
Bladder 1.669 0.110 0.891–3.129 1.063 0.853 0.558–2.025
Brain 0.760 0.542 0.314–1.838 1.984 0.143 0.793–4.966
Breast 0.126 <0.001 0.073–0.218 0.248 0.000 0.135–0.457
Cervical 0.380 0.112 0.115–1.251 0.810 0.737 0.237–2.769
Lung 1.388 0.204 0.837–2.302 1.283 0.345 0.765–2.152
H + N 1.441 0.126 0.902–2.304 1.837 0.014 1.133–2.978
Multiple 0.458 0.003 0.274–0.768 0.382 0.000 0.222–0.656
Oesophageal 2.166 0.032 1.071–4.383 1.893 0.091 0.904–3.967
Prostate 0.076 <0.001 0.027–0.215 0.076 0.000 0.027–0.218
Sarcoma 0.261 0.188 0.035–1.928 0.382 0.347 0.051–2.837
Uterine 0.231 0.046 0.055–0.972 0.285 0.092 0.066–1.229
Other 0.426 0.032 0.195–0.931 0.796 0.581 0.354–1.792
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Fig. 2. Proportion of deaths within 90 days of the start of non-palliative radiotherapy attributable to various causes.
Table 3
Univariable and Multivariable logistic regression assessing the impact of variables upon 90 DM from the start of non-palliative radiotherapy for head and neck cancer.
Univariable logistic regression Multivariable logistic regression
OR p 95% CI OR p 95% CI
Subsite
Oropharyngeal 1.000 – – 1.000 – –
Other 3.689 0.014 1.307–10.410 2.674 0.070 0.922–7.750
Age 1.045 0.002 1.017–1.073 1.038 0.007 1.010–1.067
Sex
Female 1.000 – – 1.000 – –
Male 1.294 0.483 0.630–2.656 1.424 0.348 0.680–2.982
Year 0.779 0.003 0.660–0.919 0.781 0.005 0.657–0.928
Treatment intent
Adjuvant 1.000 – – 1.000 – –
Radical 0.834 0.584 0.435–1.598 0.785 0.487 0.396–1.554
IMD
Most deprived 1.000 – – 1.000 – –
4 0.956 0.911 0.430–2.126 0.945 0.892 0.419–2.134
3 0.731 0.493 0.298–3.136 0.757 0.552 0.302–1.895
2 0.217 0.042 0.049–4.146 0.233 0.054 0.053–1.028
Most affluent 0.885 0.79 0.360–5.156 0.913 0.846 0.364–2.291
Unknown Omitted Omitted
Table 4
Univariable and multivariable logistic regression assessing the association between 90 DM and the characteristics of the non-palliative lung cancer population.
Univariable logistic regression Multivariable logistic regression
OR p 95% CI OR p 95% CI
Morphology
NSCLC 1.000 – – 1.000 – –
Small cell 2.157 0.071 0.935–4.977 3.427 0.008 1.379–8.517
Unknown 2.082 0.135 0.796–5.443 1.890 0.208 0.702–5.086
Age 1.049 0.021 1.007–1.093 1.065 0.007 1.017–1.114
Sex
Female 1.000 – – 1.000 – –
Male 2.792 0.018 1.190–6.550 2.930 0.015 1.231–6.974
Year 0.940 0.488 0.788–1.120 0.921 0.358 0.772–1.098
IMD
Most deprived 1.000 – – 1.000 – –
4 0.601 0.346 0.208–1.734 0.598 0.347 0.205–1.746
3 0.727 0.587 0.230–2.298 0.667 0.498 0.207–2.150
2 1.368 0.504 0.546–3.425 1.124 0.807 0.438–2.887
Most affluent 0.486 0.351 0.107–2.211 0.406 0.251 0.087–1.891
Unknown Omitted Omitted
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investigation was limited to lung and H + N cancer patients as,
despite using data from a large centre, over an extended time per-
iod further investigation of the oesophageal cancer, bladder cancer
and brain tumour cohorts was limited by small numbers.Head and neck cancer
An overall 90 DM of 3.86% for H + N cancer concealed a signifi-
cant reduction over the cohort period (from a peak of 6.96% in 2005
to 0.61% in 2010). COD was split predominantly between those
attributed to radiotherapy based treatment (40%) and the disease
itself (43%). 90 DM might therefore provide information to support
service improvements, however, anatomically these tumours can
pose a significant risk of mortality. As such a 90 DM of zero is unre-
alistic even if treatment related deaths can be eliminated.
The change in 90 DM over time in the H + N cancer population
warrants further discussion; a number of changes in the clinical
service may have contributed. The service moved from a stand-
alone radiotherapy centre to a large, acute teaching hospital with
all the medical support services this provides, prophylactic feeding
tube use increased, the proportion of HPV positive oropharyngeal
patients may have risen [21] and the use of induction chemother-
apy varied reflecting the changing evidence base [22]. In addition,
importantly, waiting time to the start of treatment reduced mark-
edly. It is recognised that treatment delay in H + N cancers is asso-
ciated with worse outcomes [23]. The changes in the use of
induction chemotherapy will, however, confound any analysis of
the impact of waiting time and as such this was not investigated
within the logistic regression models. The temporal variation we
saw is, however, clinically significant and if mirrored in between
centre variation might provide valuable information to guide ser-
vice change. To attribute this to any single element of the service
change would, however, ignore the complex relationships and cor-
relations that exist between these factors. The effect observed
requires, further national investigation.Lung cancer
In lung cancer overall 90 DM was 3.56%. This is significantly
lower than that reported by other groups [24], COD was predomi-
nantly disease progression (59%, with 34% attributed to comorbid-
ity) and no significant change in 90 DM was seen over time. The
observation that 90 DM in lung cancer was predominantly due to
disease progression is important. Poor stage-specific lung cancer
survival in England has previously been demonstrated, with sub-
optimal treatment usage suggested as a possible contributor [25].
Attempts to minimise 90 DM may reduce access to potentially
curative treatments for those deemed to be at higher risk of early
mortality, whether due to frailty, co-morbidity or disease stage.
As such aiming to reduce 90 DM could undermine attempts to
improve lung cancer outcomes through increased treatment access
[26,27]. Conversely, recent data support the value of intensive sup-
portive follow-up for improving survival in lung cancer patients
[28]. Further investigation is required, using national data to assess
90 DM in the context of treatment access, allowing development of
complementary measures of process quality; for example, average
waiting times and curative treatment rates. Such an approach may
provide balance and prevent inappropriate responses to a single
indicator.
These two conflicting examples highlight the varying meaning
of 90 DM in different populations. The quality of supportive ser-
vices might contribute in the head and neck population, whilst
90 DM in the lung cancer population may, potentially, be more
representative of case selection in clinical decision making. These
disease specific factors must be considered in implementing anyPlease cite this article in press as: Spencer K et al. Caution is required in the im
setting: A retrospective population-based analysis of over 16,000 episodes. Ra90 DMmetric. Additionally, variation in COD, even within diagnos-
tic groups, means this indicator will never be able to fully separate
case selection from treatment effect. As such outlying results
require in depth investigation to understand what is driving the
effect observed. Even after adjustment for case-mix variation
unmeasured confounders and failings of data capture may con-
tribute significantly to apparently outlying results.
A final element of considering the role of 90 DM in this setting is
considering its power to detect outlying results. Using H + N as an
exemplar, power calculations for a one-sample, 1-sided, proportion
test, with a = 0.05 (5% probability of a false positive) were calcu-
lated using Stata IC 14 [11,29]. Assuming a national average
90 DM of 3% cohorts of at least 257 patients are needed to deliver
80% probability of identifying a Centre with twice the national
average 90 DM. This number of H + N treatments annually will
only be seen in the largest centres (supplementary Fig. 1s). Varying
the power and type 1 error rate might allow assessment in smaller
cohorts (Table 2s) but at the cost of reduced ability to detect outly-
ing outcomes (with potential for complacency in services wrongly
identified as performing within acceptable limits) or more false
positives (with accompanying reputational damage, patient anxi-
ety and investigative resource). H + N cancer is the 4th most fre-
quently treated diagnosis in this cohort; for smaller diagnostic
groups this number of treatments annually is entirely unrealistic.
Robust annual comparisons of Centre performance using 90 DM
is, therefore, unlikely to be possible. Aggregating diagnostic groups
or time periods might provide adequate numbers, however,
heterogeneity between diagnoses and changing treatment patterns
over time could mean loss of clinical relevance and significant vari-
ation in one group concealed by others. This approach is unlikely to
be justified, although service centralisation might contribute to
clinically relevant aggregation.
We acknowledge that our investigation has a number of limita-
tions; we report a single centre study. This large dataset allows in-
depth analysis within robust local data, however, it is unclear if
these rates of 90 DM will be replicated elsewhere. Additionally,
currently available routinely collected data may not support this
analysis due to a lack of clarity about treatment intention; work
to rectify this, using linked routine datasets, is urgently needed;
COD assessment is extremely challenging, the best assessment
possible was made but we acknowledge this limitation; assess-
ment of the impact of other elements of the treatment pathway,
particularly concurrent chemotherapy was beyond the scope of
this study but should be included in future investigations.
This study does not support the adoption of the 90 DM indicator
as a centre wide measure of quality following RDCS. Further
National and International research is required to identify diagnos-
tic groups for whom this measure may have value and consider
carefully the statistical validity of National comparisons in order
to avoid encouraging complacency. Alternative longitudinal moni-
toring techniques should be considered (for example cumulative
sum charts (CUSUM) [30]. These can provide case-mix adjusted,
within centre monitoring, enabling early identification of deviation
from an acceptable baseline or persistent outliers, triggering fur-
ther investigation.
Until further work is completed to investigate this indicator,
Centres should continue to monitor their own services critically,
reviewing deaths within 90 days of RDCS to derive lessons for
future practice.Conclusion
Despite the current drive to report comparative outcomes, the
results of this study do not support the adoption of 90 DM as a cen-
tre wide indicator of quality in curative radiotherapy. If these find-plementation of 90-day mortality indicators for radiotherapy in a curative
diother Oncol (2017), http://dx.doi.org/10.1016/j.radonc.2017.07.031
K. Spencer et al. / Radiotherapy and Oncology xxx (2017) xxx–xxx 7ings are also found in more extensive, national/international stud-
ies the 90 DM indicator may have value only in specific groups.
Identifying which, if any, these are and how statistically valid out-
comes can be reported is now vital to ensure that the, much
needed, clinical indicators developed provide meaningful compar-
isons, able to facilitate improvements in care.
Conflicts of interest statement
KS, RE, ED, RB, RT, GH, EM and DSM have no conflicts of interest
to declare. AC is the National Clinical Lead for Proton therapy for
NHS England.
Funding source
Whilst undertaking this work KS was funded through the Well-
come Trust Institutional Strategic Support Fund at the University of
Leeds and subsequently a Medical Research Council Clinical
Research Training Fellowship (MR/N021339/1). EM was funded
by the Leeds Medical Research Council Medical Bioinformatics
Centre (MR/L01629X/1). RB was funded by a Cancer Research UK
Population Health Fellowship (C34080/A16438). The study spon-
sors had no involvement in the study design, in the collection,
analysis and interpretation of data; in the writing of the manu-
script; or in the decision to submit the manuscript for publication.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2017.07.
031.
References
[1] Department of Health. Improving Outcomes: A Strategy for Cancer. 2011.
[Online]. Available: https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/213785/dh_123394.pdf.
[2] NHS England» Clinical Services Quality Measures (CSQMs). [Online]. Available:
https://www.england.nhs.uk/ourwork/tsd/data-info/open-data/clinical-
services-quality-measures/. [Accessed: 09-Feb-2017].
[3] Society for Cardiothoracic Surgery – UK Cardiothoracic Centres and Outcomes.
[Online]. Available: http://www.scts.org/patients/hospitals/. [Accessed: 21-
Sep-2016].
[4] Morris EJA, Taylor E, Thomas J, et al. Thirty-day postoperative mortality after
colorectal cancer surgery in England. Gut 2011.
[5] National Oesophago-gastric Cancer Audit 2013. Clinical Effectiveness Unit. The
Royal College of Surgeons; 2013.
[6] Hunt LP, Ben-Shlomo Y, Clark E, et al. 90-day mortality after 409 096 total hip
replacements for osteoarthritis, from the National Joint Registry for England
and Wales: a retrospective analysis. Lancet 2013;382:1097–104.
[7] Wallington M, Saxon E, Bomb M, et al. 30-day mortality after systemic
anticancer treatment for breast and lung cancer in England: a population-
based, observational study. Lancet Oncol 2016;17:1203–16.Please cite this article in press as: Spencer K et al. Caution is required in the im
setting: A retrospective population-based analysis of over 16,000 episodes. Ra[8] Spencer K, Morris E, Dugdale E, et al. 30 day mortality in adult palliative
radiotherapy – A retrospective population based study of 14,972 treatment
episodes. Radiother Oncol 2015;115:264–71.
[9] Jacobson JO, Neuss M, McNiff K, et al. Improvement in oncology practice
performance through voluntary participation in the Quality Oncology Practice
Initiative. J Clin Oncol 2008;26:1893–8.
[10] Walker K, Neuburger J, Groene O, et al. Public reporting of surgeon outcomes:
low numbers of procedures lead to false complacency. Lancet
2013;382:1674–7.
[11] Dimick JB, Welch H, Birkmeyer JD. Surgical mortality as an indicator of
hospital quality: The problemwith small sample size. JAMA 2004;292:847–51.
[12] Jeremy Hunt sets out his 25-year vision for the NHS, The King’s Fund. [Online].
Available: http://www.kingsfund.org.uk/audio-video/jeremy-hunt-sets-out-
his-25-year-vision-nhs. [Accessed: 23-Sep-2016].
[13] Department of Health, Radiotherapy services in England; 2012. [Online].
Available: https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/213151/Radiotherapy-Services-in-England-2012.pdf.
[14] Osborne GE, Spendley DG, Nikapota AD. A national standard for early mortality
after external beam radiotherapy? Clin Oncol R Coll Radiol 2013;25:565.
[15] https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/6871/1871208.pdf.
[16] Office for National Statistics, http://www.ons.gov.uk/ons/guide-
method/geography/beginner-s-guide/census/super-output-areas–soas-/index.
html, 2011.
[17] ICD-10 Version: 2010. [Online]. Available: http://apps.who.int/classifications/
icd10/browse/2010/en#/II. [Accessed: 10-Feb-2017].
[18] Mort, D. For better, for worse? A review of the care of patients who died within
30 days of receiving systemic anti-cancer therapy; 2008.
[19] Cancer Action Team NHS, Cancer waiting targets; A guide (version 4).
Department of Health.
[20] Taylor C, Correa C, Duane F, et al. Estimating the risks of breast cancer
radiotherapy: evidence from modern radiation doses to the lungs and heart
and from previous randomized trials. J Clin Oncol 2017.
[21] O’Rorke MA, Ellison MV, Murray LJ, et al. Human papillomavirus related head
and neck cancer survival: A systematic review and meta-analysis. Oral Oncol
2012;48:1191–201.
[22] Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet
2008;371:1695–709.
[23] Fortin A, Bairati I, Albert M, et al. Effect of treatment delay on outcome of
patients with early-stage head-and-neck carcinoma receiving radical
radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:929–36.
[24] Nolan E, Pemberton L, Coote J. Ninety-day mortality following radical
radiotherapy for lung cancer; 2016. [Online]. Available: http://ac.els-
cdn.com/S0169500216301672/1-s2.0-S0169500216301672-main.pdf?_tid=
94dca44c-896d-11e6-8b68-00000aacb35f&acdnat=1475501622_
e4fca8b967fd82e032bfba2764df2492. [Accessed: 03-Oct-2016].
[25] Walters S, Maringe C, Coleman M, et al. Lung cancer survival and stage at
diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a
population-based study, 2004–2007. Thorax 2013;68:551–64.
[26] Wouters MWJM, Siesling S, Jansen-Lanheer M, et al. Variation in treatment and
outcome in patients with non-small cell lung cancer by region, hospital type
and volume in the Netherlands. Eur J Surg Oncol EJSO 2010;36:S83–92.
[27] Riaz SP, Luchtenborg M, Jack R, et al. Variation in surgical resection for lung
cancer in relation to survival: Population-based study in England 2004–2006.
Eur J Cancer 2012;48:54–60.
[28] Denis F, Lethrosne C, Pourel N, et al. Overall survival in patients with lung
cancer using a web-application-guided follow-up compared to standard
modalities: Results of phase III randomized trial. J Clin Oncol 2016;34.
[29] StataCorpLP. Stata power and sample-size reference manual release 13. Stata
Press; 2013.
[30] Grigg OA, Farewell VT, Spiegelhalter DJ. Use of risk-adjusted CUSUM and
RSPRTcharts for monitoring in medical contexts. Stat Methods Med Res
2003;12:147–70.plementation of 90-day mortality indicators for radiotherapy in a curative
diother Oncol (2017), http://dx.doi.org/10.1016/j.radonc.2017.07.031
